New Merck in Diabetes

Discussion in 'Merck' started by anonymous, Feb 25, 2018 at 10:35 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    what has changed since the reorg?
     

  2. anonymous

    anonymous Guest

    more uncertainty in reps, larger territories, increased performance pressures, and more layoffs later this year.
     
  3. anonymous

    anonymous Guest

    There are still too many reps. Unfortunately they did not look at real access when they redrew the maps. Many days we have to sit in our cars to have more time between calls to make the day seem longer in Veeva. Most territories would be better off as a one up territory. Its sad, but Pharma is dying. Many people are wishing that they had opted out. The company is moving away from primary care and more towards specialty and oncology. You should feel lucky that you arent stuck here with someone constantly looking over your shoulder. Treat it as a blessing if you were displaced in the last round. The new "Chronic Care" division is just a rebranded and dying primary care division.
     
  4. anonymous

    anonymous Guest

     
  5. anonymous

    anonymous Guest

    Absolutely nothing.
     
  6. anonymous

    anonymous Guest

    And you all still suck ass!

    Word on the street? More cuts ARE coming!

    Hahahaha!!

    Couldn't happen to a more deserving bunch of morons
     
  7. anonymous

    anonymous Guest

    Yes, there will be more cuts in late 4th quarter. The field is still saturated for market conditions.
     
  8. anonymous

    anonymous Guest


    My manager believes that there will be cuts by this time next year. The rollercoaster is climbing the hill again.
     
  9. anonymous

    anonymous Guest

    How is STEGasaurus sales going, are HCP's as skeptical as here in PA?
     
  10. anonymous

    anonymous Guest

    My manager says the docs are really excited about the lack of side effects vs the others
     
  11. anonymous

    anonymous Guest

     
  12. anonymous

    anonymous Guest

    The new rep is truly new at Merck. Selling dogs like Belsomra but Steglatro is setting the world on fire. My monthly sales are nothing short of spectacular
     
  13. anonymous

    anonymous Guest

    Steglatro will be number one SGLT2 by end of year
     
  14. anonymous

    anonymous Guest

    It already is the number 1 SGLT2
     
  15. anonymous

    anonymous Guest

    Idiots
    Once patent expire on januvia we are gone
     
  16. anonymous

    anonymous Guest

    They won't wait for the patent expiration. You're gone at year's end.
     
  17. anonymous

    anonymous Guest

    Generic DPP 4 and metformin allllll day long. No room for Branded agents, not as many people need a SGLT 2 as a DPP4. I hear the train a comin’ and it’s going choppa, choppa, choppa, throughhhhhh, throughhhhhh!! As in, your time is done!